Advertisement
UK markets close in 2 hours 10 minutes

  • FTSE 100

    8,075.84
    +31.03 (+0.39%)
     

  • FTSE 250

    19,765.90
    -33.82 (-0.17%)
     

  • AIM

    755.11
    +0.24 (+0.03%)
     

  • GBP/EUR

    1.1640
    +0.0013 (+0.11%)
     

  • GBP/USD

    1.2449
    -0.0004 (-0.03%)
     

  • Bitcoin GBP

    53,133.79
    -9.41 (-0.02%)
     

  • CMC Crypto 200

    1,429.32
    +5.22 (+0.37%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    82.92
    -0.44 (-0.53%)
     

  • GOLD FUTURES

    2,336.40
    -5.70 (-0.24%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,145.43
    +7.78 (+0.04%)
     

  • CAC 40

    8,131.70
    +25.92 (+0.32%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

InMode (INMD) Outpaces Stock Market Gains: What You Should Know

Zacks Equity Research

In the latest trading session, InMode (INMD) closed at $45.05, marking a +0.74% move from the previous day. This move outpaced the S&P 500's daily gain of 0.39%. Elsewhere, the Dow gained 0.17%, while the tech-heavy Nasdaq added 0.34%.

Heading into today, shares of the maker of cosmetic surgery devices had gained 0.65% over the past month, lagging the Medical sector's gain of 2.2% and the S&P 500's gain of 4.73% in that time.

INMD will be looking to display strength as it nears its next earnings release, which is expected to be February 18, 2020.

Any recent changes to analyst estimates for INMD should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

ADVERTISEMENT

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. INMD is holding a Zacks Rank of #3 (Hold) right now.

Digging into valuation, INMD currently has a Forward P/E ratio of 25.41. This valuation marks a discount compared to its industry's average Forward P/E of 26.41.

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 111, putting it in the top 44% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
InMode Ltd. (INMD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.